FIGURE 5.
Radical cure of vivax malaria with tafenoquine. Individual patient meta‐analysis 55 of freedom from recurrence of P. vivax malaria (relapse prevention) in the two tafenoquine pivotal phase 3 studies in adults. These compared tafenoquine single dose (300 mg) with a low‐dose primaquine regimen (15 mg base day for 14 days). 54 , 55 The dashed vertical line represents the prespecified noninferiority margin of an odds ratio for recurrence of 1.45 (tafenoquine vs primaquine). In Southeast Asia, which has high relapse rates, tafenoquine was significantly inferior (orange highlighting) to the low‐dose primaquine regimen (which is considered inferior to a high‐dose primaquine regimen of 30 mg base/day). Modified from Llanos‐Cuentas et al. 55 with permission